Established prognostic tools in patients with myeldysplastic syndromes (MDS) were largely derived from untreated patient cohorts. While azanucleosides are standard therapies for higher-risk (HR)-MDS, the relative prognostic performance of existing prognostic tools among patients with HR-MDS receiving azanucleoside therapy is unknown. In MDS Clinical Research Consortium database, we compared the prognostic utility of the International Prognostic Scoring System (IPSS), revised IPSS (IPSS-R), MD Anderson Prognostic Scoring System (MDAPSS), WHO-based Prognostic Scoring System (WPSS), and the French Prognostic Scoring System (FPSS) among 632 patients who presented with HR-MDS who were treated with azanucleosides as first-line therapy. Median follow-up from diagnosis was 15.7 months. No prognostic tool predicted the probability of achieving an objective response. Nonetheless, all five tools were associated with overall survival (OS, P=0.025 for the IPSS, P=0.011 for WPSS and P<0.001 for the other three tools). The corrected Akaike Information Criteria, which were used to compare OS with the different prognostic scoring systems as covariates (lower is better), were 4138 (MDAPSS), 4156 (FPSS), 4196 (IPSS-R), 4186 (WPSS) and 4196 (IPSS). Patients in the highest risk groups of the prognostic tools had a median OS from diagnosis of 11 to 16 months and should be considered for up-front transplantation or experimental approaches.Leukemia accepted article preview online, 14 October 2015. doi:10.1038/leu.2015.283.
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2020.
All research outputs
#3,035,342
of 24,003,070 outputs
Outputs from Leukemia
#806
of 5,213 outputs
Outputs of similar age
#41,815
of 283,002 outputs
Outputs of similar age from Leukemia
#8
of 63 outputs
Altmetric has tracked 24,003,070 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,213 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 283,002 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 63 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.
